STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

GSK GLAXOSMITHKLINE PUBLIC LIMITED COMPANY StockScouter® Report

9

StockScouter® Score

GLAXOSMITHKLINE PUBLIC LIMITED COMPANY, a large cap growth company in the healthcare sector, is expected to outperform the market over the next six months with less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The multi-period measure of relative price change and consistency is well above average. Positive
  • The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive
  • One or more less experienced analysts has modestly increased quarterly earnings estimates for GSK. Positive/Neutral

 

Concerns

  • The ratio of GSK’s forward price-to-earnings multiple to its estimated growth rate is well above the average of comparably-sized companies in the StockScouter universe. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that large cap stocks will be in favor, growth stocks will be in favor, and healthcare stocks will be in favor.

Expected Risk/Return

Progress: 20% done.
Progress: 100% done.
Low
High

Core Model Grades

A
C
C
A

Previous Ratings

9
8
8